This is the authors' abstract. We don't add key points for this paper.
The addition of ifosfamide and etoposide to a standard regimen does not affect the outcome for patients with metastatic disease, but it significantly improves the outcome for patients with nonmetastatic Ewing's sarcoma, primitive neuroectodermal tumor of bone, or primitive sarcoma of bone.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Grier et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: